Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease
Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.
Inclusion Criteria:
Male or female, age above or equal to 18 years at the time of signing informed consent. Japan: Male or female, age above or equal to 20 years at the time of signing informed consent
Diagnosed with type 2 diabetes mellitus
HbA1c less than or equal to 10% (less than or equal to 86 mmol/mol)
Renal impairment defined either by:
Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated. Treatment dose must be stable for at least 4 weeks prior to the date of the laboratory assessments used for determination of the inclusion criteria for renal impairment and kept stable until screening
Exclusion Criteria:
CABA, 1429, Argentina
CABA, C1060ABA, Argentina
CABA, C1430CKE, Argentina
CABA, C1440AAD, Argentina
Porto Alegre, Rio Grande do Sul 90430-001, Brazil
Ji'nan, Shandong 250013, China
Grenoble - Cédex 09, 38043, France
Saint Ingbert-Oberwürzbach, 66386, Germany
Rio, Patra, 26504, Greece
Koriyama-shi, Fukushima, Japan 963-8851, Japan
Gunma, 373-0036, Japan
Hokkaido, 062-0007, Japan
Hokkaido, 062-0007, Japan
Ipoh, Perak, 30450, Malaysia
Distrito Federal, México, D.F. 14080, Mexico
Mexico City, México, D.F. 14080, Mexico
Cosmo City, Gauteng 2188, South Africa
Zaporizhia, 69001, Ukraine